ARDS News and Press, Aridis Pharmaceuticals Inc. From 04/08/20

Aridis Pharmaceuticals (NASDAQ: ARDS ): Q4 GAAP EPS of -$0.63 beats by $0.17 . More news on: Aridis Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

SAN JOSE, Calif. , April 8, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, today reported financial and corporate resul...

New York City, NY:March 26, 2020 – Published via (Wired Release) – Recent Research and Future Market Potential of Acinetobacter Infections Treatment Market in Global Industry: 2020 Research and New Innovations in Pharmaceuticals and Healthcare Sector. The prime objective of the r...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

SAN JOSE, Calif. , March 6, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, announced today the postponement of its...

Alector (NASDAQ: ALEC ) initiated with Buy rating and $44 (52% upside) price target at Stifel. More news on: Alector, Inc., Aridis Pharmaceuticals, Inc., BioLife Solutions, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

SAN JOSE, Calif. , Feb. 18, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, announced today that it will host an In...

SAN JOSE, Calif. , Jan. 28, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (the "Company") presented a comprehensive profile of its APEX ™  platform technology at the antibody and cell engineering conference 19 th Annual PepTalk: The Protein Science Week on ...

Aridis Pharmaceuticals (NASDAQ: ARDS ) appoints  Michael A. Nazak as its Chief Financial Officer effective January 1, 2020. More news on: Aridis Pharmaceuticals, Inc., Healthcare stocks news, Read more ...

SAN JOSE, Calif. , Jan. 2, 2020 /PRNewswire/ --  Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of targeted immunotherapies using fully human monoclonal antibodies (mAbs) to treat life-threatening bacterial infection...